Comparative Effectiveness Research Alone Is Not Enough, Physicians Say
This article was originally published in The Gray Sheet
Executive Summary
Comparative effectiveness research will not improve the cost-effectiveness of the health care system if the other factors driving adoption of devices and drugs are not addressed, according to a June 17 editorial in the New England Journal of Medicine
You may also be interested in...
Stent Makers, Interventionists Downplay Impact Of BARI 2D Data
There is little debate that BARI 2D trial data unveiled last week affirmed that percutaneous coronary intervention does not extend the lives of patients with type 2 diabetes and stable ischemic heart disease, but stent manufacturers and interventionalists are scratching their heads as to why anybody would be surprised
CABG Beats DES In SYNTAX Trial; Observers Expect Little Change In Practice
Analysts and physicians predict one-year results from the SYNTAX trial will have little short-term impact on demand for drug-eluting stents, even though the devices performed worse than coronary artery bypass graft (CABG) surgery in this seminal randomized trial
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.